Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler® (Symb NIS)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00532922
First received: September 20, 2007
Last updated: June 8, 2009
Last verified: June 2009

September 20, 2007
June 8, 2009
April 2007
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00532922 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®
A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®

The purpose of this study is to investigate real practices of treatment with Symbicort Turbuhaler for 3 months in asthma and patient compliance.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Natural History, longitudinal, defined population

Asthma
Not Provided
1
Chinese asthma patient prescribed Symbicort® Turbuhaler®
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
310
November 2007
Not Provided

Inclusion Criteria:

  1. Provision of informed consent
  2. Asthmatics who has been prescribed Symbicort according to physician's judgement
  3. Usage of Symbicort should follow local prescribing information

Exclusion Criteria:

  1. Not being involved in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)
  2. No previous enrolment in the present study
Both
6 Years and older
No
Contact information is only displayed when the study is recruiting subjects
China
 
NCT00532922
NIS-RCN-SYM-2006/1
Yes
Not Provided
AstraZeneca
Not Provided
Principal Investigator: Zhou Xin Shanghai First People's Hospital
Principal Investigator: Hong Jianguo Shanghai First People's Hospital
AstraZeneca
June 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP